2026年11月2日星期一
M
Pandaigdigang Talaan
Pandaigdigang Flash News
Nuclear reactors under construction rise to 79 globally on AI demand— 日经 Nikkei AsiaAI dubbing to help Japanese companies expand global outreach— 日经 Nikkei AsiaIndonesia GDP, US midterm elections, Hong Kong financial summit— 日经 Nikkei AsiaPakistan refineries report 1,860% jump in profit amid war windfall— 日经 Nikkei AsiaAfter US midterms, democracy will face test of ability to self-correct— 日经 Nikkei AsiaThai reformists became too technocratic, party ex-leader Pita says— 日经 Nikkei AsiaJapan bamboo chopsticks catch on in South Korea— 日经 Nikkei AsiaOn India's east coast, tidepooling inspires marine conservation— 日经 Nikkei AsiaNuclear reactors under construction rise to 79 globally on AI demand— 日经 Nikkei AsiaAI dubbing to help Japanese companies expand global outreach— 日经 Nikkei AsiaIndonesia GDP, US midterm elections, Hong Kong financial summit— 日经 Nikkei AsiaPakistan refineries report 1,860% jump in profit amid war windfall— 日经 Nikkei AsiaAfter US midterms, democracy will face test of ability to self-correct— 日经 Nikkei AsiaThai reformists became too technocratic, party ex-leader Pita says— 日经 Nikkei AsiaJapan bamboo chopsticks catch on in South Korea— 日经 Nikkei AsiaOn India's east coast, tidepooling inspires marine conservation— 日经 Nikkei Asia

Author Correction: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial

Pinagmulan Nature 医学研究6 araw ang nakalipas
Buod ng nilalaman

Ang site na ito ay nagbibigay lamang ng index ng pamagat at buod; ang buong nilalaman at copyright ay pag-aari ng orihinal na tagapaglathala. Mangyaring i-click ang orihinal na link upang basahin.

Pumunta sa orihinal na teksto
Kabilang channel
Kalusugan
Kabilang rehiyon
Pandaigdigang pananaw
Wika ng orihinal
English
Numero ng entry
health-a90987bb

Comments 0 comments

No comments yet. Be the first.

Author Correction: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial · Pandaigdigang Talaan